Loading…
← CockpitCompetitor Analysis › 7827.TW HanchorBio Inc.Open in the cockpit ↗

HanchorBio Inc.7827.TWCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Biotechnology
Mkt cap
$462M
US dollars, full cap
Free float
38%
of shares outstanding
$/day
$769,771
20-day average traded
Fwd P/E
2.3×
forward earnings
ROIC−WACC
n/a
WACC 8.3%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · TWDNT$119.50
1D0.0%
1W+0.4%
1M-27.1%
3M-25.8%
6Mn/a
YTDn/a
1Yn/a
ATR %5.2%
52w lowhigh36.1% off high

What HanchorBio does

No business profile yet.

HanchorBio at a glance

Size HanchorBio (7827.TW) is a Taiwan Health Care company (Biotechnology) with a market value of $462M, the 454th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$119.50 on 18 Nov 2026.

Growth The operating margin is -4,672.8% (peer median -6.9%).

Valuation It trades at 2.3× forward earnings against a peer median of 33.9× (cheapest of 6).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

HanchorBio financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$27.7MNT$312MNT$0NT$0NT$3.36M
Revenue growth———-100%—
Gross profit-NT$39.5MNT$274M-NT$37.4M-NT$33.9M-NT$24.8M
EBITDA-NT$1.25B-NT$330M-NT$915M-NT$504M-NT$485M
Net income-NT$1.01B-NT$277M-NT$1.35B-NT$591M-NT$446M
Free cash flow-NT$1.04B-NT$336M-NT$626M-NT$462M-NT$405M
Capital expenditureNT$41.8MNT$18.7MNT$19.0MNT$23.2MNT$70.8M
Total debtNT$238MNT$101MNT$46.3MNT$61.0MNT$45.2M

Quarterly statements and history in the cockpit →

HanchorBio competitors and peer comparison

How HanchorBio compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

HanchorBio against its 20 peers (data as of 18 Nov 2026)
Measure7827.TWPeer medianRank in peer set
1-month return-27.1%-7.3%3rd lowest of 21
Distance from 52-week high-36.1%-41.1%10th highest of 21
Operating margin-4,672.8%-6.9%2nd lowest of 15
Forward P/E2.3×33.9×cheapest of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
HanchorBio 7827.TWTaiwan$462Mn/an/a-4,673%2.3×n/an/a
DiaMedica Therapeutics DMACUnited States$463M+50%n/an/an/an/an/a
Kamada KMDAUnited States$465M+3%+5%15%17.9×5.0%+6.5%
Shattuck Labs STTKUnited States$455M-28%-100%n/an/an/an/a
TenNor Therapeutics Suzhou 6872.HKHong Kong$470Mn/an/an/an/an/an/a
Komipharm International 041960.KSSouth Korea$454M-2%-6%-1%n/an/an/a
Fennec Pharmaceuticals FENCUnited States$471M+37%+71%5%16.9×58.8%+204.7%
Qurient 115180.KSSouth Korea$452M-56%-14%-512%n/an/an/a
Neurogene NGNEUnited States$479M-14%-100%n/an/an/an/a
Monopar Therapeutics MNPRUnited States$479M+9%n/an/an/an/an/a
TaiMed Biologics 4147.TWOTaiwan$480M+19%+7%-31%n/an/an/a
EirGenix 6589.TWTaiwan$444M+15%+58%-51%n/an/an/a
Arvinas ARVNUnited States$443M-26%-12%-10%n/an/an/a
Crescent Biopharma CBIOUnited States$482M-34%n/a-1,217%n/an/an/a
IRulya Therapeutics IRLAUnited States$440M+88%n/an/an/an/an/a
Berry Genomics 000710.SZChina$439M-17%-2%-24%n/an/an/a
CHO Pharma 6586.TWOTaiwan$488M+24%-47%-17,694%n/an/an/a
Qingdao Vland Biotech 603739.SSChina$437M-24%+5%7%33.9×7.7%+7.3%
Liaoning Dingjide Petrochemical 603255.SSChina$490M-24%+70%5%37.5×n/an/a
Scinopharm Taiwan 1789.TWTaiwan$435M-2%-5%-4%39.4×2.1%+0.5%
Sinotherapeutics 688247.SSChina$494M-19%-17%0%n/a29.4%+7.0%

Questions

Which companies are HanchorBio's closest peers?
The cockpit's peer set: DiaMedica Therapeutics (DMAC), Kamada (KMDA), Shattuck Labs (STTK), TenNor Therapeutics Suzhou (6872.HK), Komipharm International (041960.KS), Fennec Pharmaceuticals (FENC), Qurient (115180.KS), Neurogene (NGNE).
Is HanchorBio expensive compared with its peers?
On forward p/e it trades at 2.3× against a peer median of 33.9×, cheapest of 6 in its peer set.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.